<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128137</url>
  </required_header>
  <id_info>
    <org_study_id>2018-003905-25</org_study_id>
    <nct_id>NCT04128137</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension</brief_title>
  <official_title>Evaluation of Efficacy and Tolerance of Fludrocortisone (Flucortac) in the Treatment of Orthostatic Neurogenic Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H.A.C. PHARMA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H.A.C. PHARMA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood&#xD;
      pressure depression after 5 minutes of active orthostatism in patients with neurogenic&#xD;
      orthostatic hypotension (HON) symptomatic, despite treatment with non-drug measures with or&#xD;
      without midodrine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to demonstrate the efficacy of FLU on systolic blood pressure&#xD;
      depression in patients with neurogenic orthostatic hypotension. The study is randomised&#xD;
      versus placebo.Each patient will be followed for a maximum of 5 months, with no more than 8&#xD;
      visits to the investigator (V0 at Day-7, V1 at D0, V2 at D7, V3 at D+14, V4 at D+21, V5 at D+&#xD;
      28, V6 at D+56 and V7 only for patients on the FLU arm at D+140.&#xD;
&#xD;
      The presence of a comparator control group with placebo permits to evaluate the efficacy and&#xD;
      the tolerance of FLU independently of the natural evolution of the pathology, in patients&#xD;
      benefiting from a non-drug or possibly medicated treatment (midodrine) but insufficient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic BP diminution</measure>
    <time_frame>8 weeks</time_frame>
    <description>Systolic BP diminution when moving from supine to standing, measured with a semi-automatic blood pressure monitor&#xD;
- AP in upright position: the lowest value of the measurements obtained every minute, for 5 minutes after rising.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Neurogenic Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>fludrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of flucortac and same diagram of administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose</description>
    <arm_group_label>fludrocortisone</arm_group_label>
    <other_name>Flucortac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of orthostatic hypotension (HO), ie a blood pressure drop&gt; 20 and / or 10&#xD;
             mmHg within 3 minutes after active and symptomatic lifting&#xD;
&#xD;
          -  Patient suffering from a neurological disease&#xD;
&#xD;
          -  orthostatic neurogenic hypotension persistent and symptomatic despite non-drug&#xD;
             measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to FLU or any of its excipients&#xD;
&#xD;
          -  non orthostatic neurogenic hypotension&#xD;
&#xD;
          -  History of proven heart failure&#xD;
&#xD;
          -  History of left ventricular systolic dysfunction&#xD;
&#xD;
          -  Uncompensated hypokalemia&#xD;
&#xD;
          -  Patient with poorly balanced Grade 3 hypertension&#xD;
&#xD;
          -  Pregnant patient at the time of inclusion&#xD;
&#xD;
          -  Nursing patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel SENARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine DENICOURT</last_name>
    <phone>02 31 47 92 46</phone>
    <email>catherine.denicourt@hacpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Broca (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HANON, MD</last_name>
      <email>Olivier.hanon@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

